Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis

NCT04524273 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04524273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 15, 2020
Completion date
June 7, 2029
Enrollment
238 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis